BioMed Realty and CordenPharma Colorado Team Up for Expansion of Peptide Development Lab in New LEED® Gold-Certified Facility at Flatiron Park in Boulder

Full-building, 15-year lease for 64,000 square feet enables CDMO CordenPharma Colorado to power next-generation peptide development

BOULDER, Colo.--(BUSINESS WIRE)--BioMed Realty, the largest private owner and operator of real estate for the life science, technology and innovation industries, announced that CordenPharma Colorado, a leading peptide drug substance Contract Development and Manufacturing Organization (CDMO), has leased 64,000 square feet at Flatiron Park’s 5505 Central – Boulder’s first purpose-built speculative lab building – near the existing CordenPharma Colorado facility.

Flatiron Park is BioMed Realty’s premier Boulder campus, supporting life science, quantum and technology tenants through highly resilient infrastructure, flexible building solutions, and a thoughtfully curated campus environment. CordenPharma Colorado’s 15-year lease reinforces Flatiron Park’s position as a critical hub for innovation, and validates BioMed Realty’s substantial, long-term investment in the Boulder innovation ecosystem.

CordenPharma Colorado will be the sole tenant at 5505 Central. The new LEED^® Gold-certified facility features robust power capacity, adaptable lab grids, advanced mechanical and utility systems, and efficient waste disposal to support complex scientific operations. Strategically located adjacent to CordenPharma Colorado’s large-scale peptide manufacturing facility, the space will house process development and analytical services, enabling seamless integration of advanced peptide Active Pharmaceutical Ingredient (API) production from development through commercialization.

Beyond Colorado, the expanded peptide development capabilities created at this location will be integrated into CordenPharma’s growing global network across Europe and the U.S.

“We’re proud to deliver the first purpose-built lab building at Flatiron Park, designed to meet the flexibility and performance needs of sophisticated science users,” said Jon Bergschneider, President, West Coast Markets at BioMed Realty. “Combined with a connected campus experience, curated amenities, Discover Here programming, and a tenant-first operating model, Flatiron Park supports innovation today while enabling long-term growth.”

“We’re excited to partner with BioMed Realty on this project to accelerate our strategic growth and meet customer demand for complex peptide outsourcing, while creating additional jobs and attracting research talent to the region,” said Michael Landau, Managing Director of CordenPharma Colorado. “With our strong team and strategic vision, backed by our global facility network, these new labs will grow the life sciences sector in Boulder. As a CDMO, our Development Laboratories are foundational in delivering effective support to customers and their patients.”

Jennifer Chavez, Senior Director, Leasing for BioMed Realty, added: “The addition of CordenPharma to Flatiron Park reflects the vital role BioMed Realty plays in supporting Boulder’s innovation ecosystem. We provide the high-quality, reliable infrastructure and adaptable environments leading companies like CordenPharma need to succeed.”

To learn more about CordenPharma Colorado career opportunities or join their talent pool, visit CordenPharma Colorado’s career page.

About BioMed Realty

BioMed Realty is the leading provider of real estate solutions for the life science, technology and innovation industries. The company owns and operates 17 million square feet of purpose-built laboratory and office space across the world’s top innovation hubs, including Boston/Cambridge, San Francisco, San Diego, Seattle, Boulder, and Cambridge, U.K. With an additional 1.5 million square feet of Class A properties under development, BioMed delivers flexible, reliable, and sustainable environments designed to accelerate discovery and keep world-changing work moving. Backed by more than 20 years of experience, BioMed Realty provides the confidence and partnership that fuel life-enhancing and world-changing innovation. To learn more, visit www.biomedrealty.com.

About CordenPharma Colorado

CordenPharma Colorado is part of the CordenPharma Group, a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.

With scientific expertise and partnership at its core, CordenPharma provides customers with high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).

The CordenPharma Group is comprised of 11 facilities across Europe and North America. In the 2025 financial year, the organization generated sales of €960 million and had over 3,000 employees.

Please visit cordenpharma.com or the CordenPharma Colorado Career Page for more information. | Follow CordenPharma on LinkedIn.